A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

por Kobayashi, Shigeto, Harigai, Masayoshi, Mozaffarian, Neelufar, Pangan, Aileen L., Sharma, Shringi, Brown, L. Steven, Miyasaka, Nobuyuki
Publicado 2011

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

por Ramanathan, Srini, Di Paolo, Julie A., Jin, Feng, Shao, Lixin, Sharma, Shringi, Robeson, Michelle, Kearney, Brian P.
Publicado 2016

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjec...

por Edlund, Helena, Bellanti, Francesco, Liu, Huan, Vishwanathan, Karthick, Tomkinson, Helen, Ware, Joseph, Sharma, Shringi, Buil‐Bruna, Núria
Publicado 2021

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors

por Pilla Reddy , Venkatesh, Fretland, Adrian J., Zhou, Diansong, Sharma, Shringi, Chen, Buyun, Vishwanathan, Karthick, McGinnity, Dermot F., Xu, Yan, Ware, Joseph A.
Publicado 2021

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies

por Edlund, Helena, Buil‐Bruna, Núria, Vishwanathan, Karthick, Wei, Helen, Raman, Rakesh, de Kock, Miné, He, Zhongqing, Liu, Huan, Baek, Marshall, Ware, Joseph, Patel, Priti, Tomkinson, Helen, Sharma, Shringi
Publicado 2021

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

por Xu, Yan, Izumi, Raquel, Nguyen, Helen, Kwan, Anna, Kuo, Howard, Madere, Jeannine, Slatter, J. Greg, Podoll, Terry, Vishwanathan, Karthick, Marbury, Thomas, Smith, William, Preston, Richard A., Sharma, Shringi, Ware, Joseph A.
Publicado 2022

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

por Jurczak, Wojciech, Elmusharaf, Nagah, Fox, Christopher P., Townsend, William, Paulovich, Amanda G., Whiteaker, Jeffrey R., Krantz, Fanny, Wun, Chuan-Chuan, Parr, Graeme, Sharma, Shringi, Munugalavadla, Veerendra, Manwani, Richa, Dean, Emma, Munir, Talha
Publicado 2023

P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANA...

por Shortt, Jake, Feldman, Tatyana, Collins, Graham, Zain, Jasmine, Khot, Amit, Seok Kim, Jin, Morschhauser, Franck, Min Kim, Tae, Roderick, Justine, Lim Yoon, Jeong, Sharma, Shringi, Saeh, Jamal, Dai, Jiale, Reyes, Ruben, Olsson, Richardp, Luigi Zinzani, Pier
Publicado 2023

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

por Sharma, Shringi, Pepin, Xavier, Burri, Harini, Zheng, Lianqing, Kuptsova‐Clarkson, Nataliya, de Jong, Anouk, Yu, Ting, MacArthur, Holly L., Majewski, Michal, Byrd, John C., Furman, Richard R., Ware, Joseph A., Mann, James, Ramies, David, Munugalavadla, Veerendra, Sheridan, Louise, Tomkinson, Helen
Publicado 2022

P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

por Desai, Pinkal, Lonial, Sagar, Cashen, Amanda, Kamdar, Manali, Blachly, James S., Flinn, Ian W., O’brien, Susan, Garcia, Jacqueline, Korde, Neha, Moslehi, Javid, Wey, Margaret, Cheung, Patricia, Sharma, Shringi, Olabode, Damilola, Chen, Hong, Ali Syed, Firasath, Liu, Mary, Saeh, Jamal, Tibes, Raoul, Andrade, Marcio, Kadia, Tapan
Publicado 2023

P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

por Marconi, Giovanni, Arslan, Shukaib, Fleming, Shaun, Curti, Antonio, S Blachly, James, Martinelli, Giovanni, Giovanni Della Porta, Matteo, Bajel, Ashish, Sauer, Tim, Crysandt, Martina, Pigneux, Arnaud, Konopleva, Marina, Marmor, Yotvat, Sharma, Shringi, Elgeioushi, Nairouz, Rowe, Emily, Cheung, Patricia, Jahn, Ekaterina, Saeh, Jamal, Tibes, Raoul, Zumla Cader, Fathima, Jain, Nitin
Publicado 2023

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

por Roschewski, Mark, Patel, Manish R., Reagan, Patrick M., Saba, Nakhle S., Collins, Graham P., Arkenau, Hendrik-Tobias, de Vos, Sven, Nuttall, Barrett, Acar, Melih, Burke, Kathleen, White, Rafael D., Udriste, Maria, Sharma, Shringi, Dougherty, Brian, Stetson, Daniel, Jenkins, David, Mortlock, Andrew, Forcina, Alessandra, Munugalavadla, Veerendra, Flinn, Ian
Publicado 2023